Considering the fact that normal weight patients do not experience an obesity-mediated increase in bone mineral density, it is possible that normal weight patients experience an increased risk of osteoporotic fractures when receiving extended aromatase inhibition. This evidence concerns the gene CYP19A1 and obesity due to melanocortin 4 receptor deficiency.